News
BMY
76.84
-0.21%
-0.16
5 NYSE Stocks To Watch And Buy: Here Are Fundamental And Technical Reasons Why
There's no better time than to build a strong watchlist during a serious market correction. This story covers five NYSE stocks to watch and consider buying. In 2022, the NYSE's composite index is outperforming its Nasdaq sibling.
Investor's Business Daily · 1d ago
Bristol Myers Squibb (BMY) Dips More Than Broader Markets: What You Should Know
Bristol Myers Squibb (BMY) closed the most recent trading day at $78.28, moving -0.53% from the previous trading session.
Zacks · 2d ago
Canada approves Bristol-Myers' Opdivo for bladder cancer patients with certain conditions
Bristol-Myers Squibb's (NYSE:BMY) Canadian arm on Tuesday said the country's drug regulator had approved its cancer medicine Opdivo for the treatment of adults with bladder cancer with certain conditions. Health
Seekingalpha · 3d ago
Health Canada Approves OPDIVO® (nivolumab) as Monotherapy for the Adjuvant treatment of Adults with Urothelial Carcinoma (UC) at High Risk of Recurrence after Undergoing Radical Resection of UC
Today, Bristol Myers Squibb Canada (BMS) announced Health Canada has issued a Notice of Compliance with Conditions (NOC/c) for OPDIVO®, as a monotherapy for the adjuvant treatment of adult patients with urothelial carcinoma (UC) who are at high risk of rec...
CNW Group · 3d ago
Dow Jones Rallies As Nike Falls On Weak Sales Guidance
The Dow Jones Industrial Average rose 200 points Tuesday, looking to rebound from Monday's losses. Nike stock tumbled on weak guidance.
Investor's Business Daily · 3d ago
Here's How to Treat Bristol-Myers Squibb's Charts
Pharmaceutical giant Bristol-Myers Squibb has broken out to a new high for the move up. The On-Balance-Volume (OBV) line has made a new high for the move up to confirm and support the recent price increase. The MACD oscillator has turned lower but has c...
TheStreet.com · 4d ago
Bristol Myers (BMY) Breyanzi Gets FDA Nod for Label Expansion
Bristol Myers' CAR T cell therapy Breyanzi was approved by the FDA for relapsed or refractory large B-cell Lymphoma after one prior therapy.
Zacks · 4d ago
Bristol-Myers Squibb Company (NYSE:BMY) Stock Goes Ex-Dividend In Just Two Days
Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Bristol-Myers...
Simply Wall St. · 4d ago
Bristol Myers Squibb Wins FDA Approval for Blood Cancer Drug
MT Newswires · 4d ago
UnitedHealth, Shockwave Lead 5 Healthy Stocks Breaking Out Or Setting Up
Shockwave Medical and UnitedHealth lead five stocks that are setting up or breaking out as the medical sector is the healthiest market area.
Investor's Business Daily · 6d ago
BRIEF-U.S. FDA Approves Bristol Myers Squibb'S Car T Cell Therapy Breyanzi For Relapsed Large B-Cell Lymphoma
reuters.com · 06/24 23:09
U.S. FDA Approves Bristol Myers Squibb’s CAR T Cell Therapy Breyanzi® for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy
PRINCETON, N.J., June 24, 2022--U.S. FDA Approves BMS’s CAR T Cell Therapy Breyanzi for Use After One Prior Therapy for Relapsed or Refractory Large B-cell Lymphoma
Business Wire · 06/24 23:05
This Is What Whales Are Betting On Bristol-Myers Squibb
Someone with a lot of money to spend has taken a bullish stance on Bristol-Myers Squibb (NYSE:BMY). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.
Benzinga · 06/24 20:02
Bristol-Myers MS drug linked to better COVID response with mRNA shots
Bristol Myers Squibb (NYSE:BMY) said on Friday that the patients taking its multiple sclerosis therapy drug Zeposia (ozanimod) were more likely to develop COVID-19 antibodies to mRNA vaccines compared to
Seekingalpha · 06/24 18:13
Bristol-Myers Squibb Highlights New Data On Immune Response To Covid-19 Vaccines In Individuals With Relapsing Forms Of Multiple Sclerosis Treated With Zeposia
New Data Highlight Immune Response to COVID-19 Vaccines in Individuals with Relapsing Forms of Multiple Sclerosis Treated with Zeposia (ozanimod) Analysis of ongoing DAYBREAK open-label extension trial of Zeposia showed
Benzinga · 06/24 16:53
Bristol Myers Squibb Presents New Data Showing Effect of Early Zeposia (ozanimod) Treatment in Improving and Preserving Cognitive Function in People With Relapsing Multiple Sclerosis
PRINCETON, N.J., June 24, 2022--Bristol Myers Squibb (NYSE:BMY) today announced new post-hoc analyses from the Zeposia (ozanimod) Phase 3 DAYBREAK open-label extension (OLE) and Phase 3 SUNBEAM trials, showing early Zeposia use demonstrated cognitive benef...
Business Wire · 06/24 16:52
New Data Highlight Immune Response to COVID-19 Vaccines in Individuals with Relapsing Forms of Multiple Sclerosis Treated with Zeposia (ozanimod)
PRINCETON, N.J., June 24, 2022--Bristol Myers Squibb (NYSE:BMY) today announced new data on COVID-19 vaccine responses in participants treated with Zeposia (ozanimod) from the ongoing Phase 3 DAYBREAK open-label extension (OLE) study in relapsing multiple ...
Business Wire · 06/24 16:51
Bristol-Myers Squibb hits 52-week high; shares up 27% YTD
Bristol-Myers Squibb (NYSE:BMY) hit a 52-week high of $78.82 Friday morning. Year-to-date, shares are up 27%. Bristol (BMY) is also the best performing large pharma company YTD. Wells Fargo recently included
Seekingalpha · 06/24 15:30
Bristol Myers Squibb (BMY) Gains As Market Dips: What You Should Know
In the latest trading session, Bristol Myers Squibb (BMY) closed at $76.55, marking a +0.1% move from the previous day.
Zacks · 06/22 21:50
IBD Stock Of The Day: Bristol Myers Eyes Breakout After $4.1 Billion Buyout
Bristol Myers Squibb is the IBD Stock Of The Day as BMY stock bounds off its 50-day line, presenting investors with an early entry.
Investor's Business Daily · 06/22 21:19
More
Webull provides a variety of real-time BMY stock news. You can receive the latest news about Bristol-Myers Squibb Co through multiple platforms. This information may help you make smarter investment decisions.
About BMY
Bristol-Myers Squibb Company is a biopharmaceutical company. The Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. It offers products for a range of therapeutic classes, which include oncology, immunology, cardiovascular and fibrosis. Its pharmaceutical products include chemically-synthesized or small molecule drugs and products produced from biological processes, called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. Its products include Revlimid, Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Sprycel, Yervoy, Abraxane, Empliciti, Reblozyl, Inrebic, Onureg, Zeposia, Vidaza, Baraclude and Breyanzi. Its products are sold to wholesalers, distributors, pharmacies, retailers, hospitals, clinics and government agencies.